© 2022 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular content related to diabetes technology from 2022. Of note, this list does not include regulatory news or guideline recommendations as both of these topics were covered in their own year in review recaps.
New data from a small study assessing ease of uptake of the Dexcom G7 continuous glucose monitoring system is underlining the impact of advancing technology on accessibility and use of newer CGM systems as part of diabetes management.
A 10-person study assessing uptake of the Dexcom G7 CGM system among a population of older adults with the aid of a certified diabetes care and education specialist, results indicate that G7 CGM system required half as many steps to set up and deploy as the G6 system, with the system’s system usability scale survey scores indicating excellent usability.
In the first of 4 special edition episodes from ADA 2022, Diabetes Dialogue hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics’ Insulin-Only Bionic Pancreas.
Full data from the 13-week trial of the iLet insulin-only bionic pancreas details the improvements in glycemic control achieved with use of the bionic pancreas in adults and children with type 1 diabetes aged from as young as 6 years old and up to 79 years of age.
With funding from the National Institute of Diabetes and Digestive and Kidney Diseases, results of the 13-week randomized trial suggest use of BetaBionics’ iLet bionic pancreas was associated with greater reductions in HbA1c than standard care, with those using a bionic pancreas experience a greater percentage of time in range as well.
Increased scanning can decrease fear of hypoglycemia among people with type 1 diabetes using intermittently scanned CGM systems, according to the results of a new study.
An analysis of clinical data and ambulatory glucose profile reports from an outpatient clinic in Poland, results of the study indicate increased frequency of scanning with intermittently scanned CGM devices was associated with improve glycemic control and decreased fear of hypoglycemia among people with type 1 diabetes.
The Dexcom G7 Continuous Glucose Monitoring (CGM) System rollout began on October 4 with the company announcing its availability for people with diabetes aged 2 years and older in the United Kingdom, Ireland, Germany, Austria, and Hong Kong, with a rollout in New Zealand and South Africa expected within the following weeks.
Related Content: